Systemic juvenile idiopathic arthritis and macrophage activation syndrome: Case

Framing the case

This four-year-old girl with the systemic JIA who develops the falling platelets and the rising ferritin under the tocilizumab with the normal CRP is the textbook presentation of the paradoxical macrophage activation syndrome. The framework that organises the case is the recognition that the interleukin-six blockade masks the usual warning signs of the MAS, so the diagnosis rests on the trend of the platelets and the ferritin rather than the fever and the CRP. [5]

The initial presentation and the diagnosis

The quotidian fever that returns to baseline, the evanescent salmon-pink rash, and the arthritis together fulfil the ILAR criteria for the systemic subtype of juvenile idiopathic arthritis. The negative autoantibodies, the leukocytosis and the thrombocytosis are the typical laboratory features. The modern understanding is that sJIA is an autoinflammatory disease driven by the innate-immune interleukin-one and interleukin-six axis, and the 2024 EULAR and PReS recommendations reframe it as Still disease. The first-line biologic is the interleukin-one blockade, and the tocilizumab is the interleukin-six blockade that was started in this case. [9]

The recognition of the paradoxical MAS

The falling platelet count from four hundred and eighty to one hundred and fifty and the rising ferritin from six hundred to three thousand eight hundred in a child whose disease appeared controlled are the signs of the macrophage activation syndrome. The normal CRP does not exclude the MAS because the tocilizumab suppresses the interleukin-six and the CRP, masking the usual inflammatory signal. The mechanism is that the tocilizumab blocks the interleukin-six but not the interferon-gamma, so the underlying interferon-gamma cytokine storm of the MAS continues beneath the masked exterior. [5][10]